UiPath (PATH) stock slides after Q4 FY26 results as Needham upgrades to Buy on ARR and free cash flow growth; AI ARR hits $200M.

It's still too early to say whether UiPath will ultimately end up, on net, as benefitting from or being harmed by AI adoption. Read why PATH stock is a Sell.

NEW YORK, February 23, 2026--(BUSINESS WIRE)--UiPath (NYSE: PATH), a global leader in agentic automation, today announced new agentic AI solutions for the healthcare industry for providers and payers ...

UiPath (PATH) closed the most recent trading day at $10.94, moving -3.36% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.1%. Meanwhile, the Dow ...

UiPath Inc PATH reported better-than-expected financial results for the fourth quarter of fiscal 2026 after the market close ...